MRUS - AstraZeneca's Tagrisso-Chemo Combo Data In Lung Cancer Sets High Bar For Johnson & Johnson's Cancer Drug: Analyst | Benzinga
On Sunday night, AstraZeneca Plc (NASDAQ: AZN) presented the Phase 3 FLAURA2 results evaluating Tagrisso plus chemotherapy versus Tagrisso monotherapy as first-line treatment for patients with EGFR mutant lung cancer.
The combination resulted in a significant benefit in progression-free survival (PFS), with roughly a 9-month absolute improvement in median PFS and a hazard ratio of 0.62.
William Blair writes that the results raise the efficacy bar for Johnson & Johnson's (NYSE: JNJ) MARIPOSA Phase 3 trial evaluating Rybrevant plus lazertinib, expected later this year.
The analyst, Matt Phipps, further highlights that the absence of clear trends in overall survival and increased chemotherapy-related toxicity does not ...